Is Taurine Blood Pressure Systematic Review safe?

Updated July 2026

Quick Answer

Taurine Blood Pressure Systematic Review has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: BACKGROUND: SARS-CoV-2 infection can induce cellular senescence, resulting in chronic inflammation and senescence-associated secretory phenotype observed in post-acute sequalae of COVID-19 (PASC).

Key Takeaways

  • 01BACKGROUND: SARS-CoV-2 infection can induce cellular senescence, resulting in chronic inflammation and senescence-associated secretory phenotype observed in post-acute sequalae of COVID-19 (PASC). [Wang K (2026)]
  • 02Preclinical evidence suggests taurine protects against cellular senescence, telomerase deficiency, DNA damage, and mitochondrial dysfunction, indicating its potential therapeutic role in PASC. [Wang K (2026)]
  • 03METHODS: We systemically searched MEDLINE, Embase, Cochrane Library, and Scopus through 21st March 2025 for clinical trials investigating taurine supplementation in systemic perturbations associated with PASC. [Wang K (2026)]
  • 04Taurine, a conditionally essential amino acid with potent anti-inflammatory and antioxidant properties, is naturally upregulated during COVID-19 convalescence. [Wang K (2026)]
The current Migaku evidence database contains 2 reusable source documents for Taurine Blood Pressure Systematic Review. This answer focuses on safety, limits, and clinician-discussion contexts. - BACKGROUND: SARS-CoV-2 infection can induce cellular senescence, resulting in chronic inflammation and senescence-associated secretory phenotype observed in post-acute sequalae of COVID-19 (PASC). [Wang K (2026); evidence level 1] - Preclinical evidence suggests taurine protects against cellular senescence, telomerase deficiency, DNA damage, and mitochondrial dysfunction, indicating its potential therapeutic role in PASC. [Wang K (2026); evidence level 1] - METHODS: We systemically searched MEDLINE, Embase, Cochrane Library, and Scopus through 21st March 2025 for clinical trials investigating taurine supplementation in systemic perturbations associated with PASC. [Wang K (2026); evidence level 1] - Taurine, a conditionally essential amino acid with potent anti-inflammatory and antioxidant properties, is naturally upregulated during COVID-19 convalescence. [Wang K (2026); evidence level 1] - Recent experimental evidence suggests that taurine (2-aminoethanesulfonic acid) deficiency contributes to these conditions, despite taurine being classified as a conditionally essential amino acid. [Chu MHM (2026); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis.
  2. Effects of taurine supplementation on metabolic health and biological aging in healthcare workers: A protocol for a triple-blinded, Bayesian-optimized phase II randomized controlled trial.